関連する実験動画

Updated: Aug 17, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

r-hirudinによる特異的トロンビン阻害による壁血栓の溶解:ヘパリンとアスピリンとの比較

B J Meyer¹, J J Badimon, J H Chesebro

¹Department of Medicine, University Hospital Inselspital, Bern, Switzerland. bmeyer@insel.unibe.ch

|March 12, 1998

まとめ

r-hirudinによる直接的トロンビン阻害は,急性冠動脈症候群における壁の血栓のサイズと成長を効果的に減少させます. この抗凝固剤は,低用量ヘパリンよりも効果が高く,有望な治療戦略を提供している.

科学分野:

心血管科学の研究について
トロンボシスと血液静止症
薬理学薬理学とは

背景:

残留壁血栓は,急性冠動脈症候群における再発性血栓性イベントの危険因子である.
壁性血栓に対する抗血栓剤の影響を理解することは,ACSの管理に極めて重要です.

研究の目的:

トロンブスの成長過程で,先行形成された壁状トロンブスに対する抗血栓剤および抗血小板剤の効果を評価する.
r-hirudin,ヘパリン,アスピリンの効果を比較して,壁血栓の進行を抑制する.

主な方法:

傷ついた動脈の壁に豚の血を注入することで,豚で壁に描かれた血栓モデルが作成されました.
血栓の形成と成長は,r-hirudin,ヘパリン,アスピリン,またはプラセボによる治療の後,形態測定で測定されました.

主要な成果:

R-ヒルジンは,壁血栓の領域を48%大幅に減少させ,高用量ヘパリンよりも効果的に血栓の成長を抑制しました.
ヘパリンは,血栓増殖の投与量依存的阻害を示し,プラズマ濃度と逆相関を示した.
アスピリン単独では,プラセボと比較して,血栓の大きさを有意に変化させなかった.

結論:

r-hirudinによる直接的なトロンビン阻害は,トロンブスの成長を完全に防止し,既存の壁状トロンブスの解消を促進します.
R-hirudinは,冠動脈狭窄症を模倣した状態で壁血栓を管理するために,低抗凝固レベルでの高用量ヘパリンよりも効果的です.
これらの発見は,壁血栓による急性冠動脈症候群の管理において,直接的トロンビン阻害剤の潜在力を強調しています.

さらに関連する動画

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

関連する概念動画

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...